Diagnostic Name (Manufacturer)	Indication - Sample Type	Drug Trade Name (Generic) NDA / BLA	NDA Number	Biomarker(s)	Biomarker(s) (Details)	PMA / 510(k) / 513(f)(2) / HDE (Approval / Clearance / Grant Date)	Date	Comments/Indication Details	OncoTree	OncoKB Drug name	OncoKB Gene	OncoKB Biomarker	Specimen_Type
Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.)	Non-Small Cell Lung Cancer (NSCLC) - Tissue	Xalkori (crizotinib) NDA 202570	NDA 202570	ALK	ALK gene rearrangements	P110012	08/26/2011	Indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK or ROS1-positive as detected by an FDA-approved test	NSCLC	Crizotinib	ALK	Fusions	FISH
Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.)	Non-Small Cell Lung Cancer (NSCLC) - Tissue	Alunbrig (brigatinib) NDA 208772	NDA 208772	ALK	ALK gene rearrangements	P110012/S020	05/22/2020	Indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK or ROS1-positive as detected by an FDA-approved test	NSCLC	Brigatinib	ALK	Fusions	FISH
cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc.)	Melanoma - Tissue	Zelboraf (vemurafenib) NDA 202429	NDA 202429	BRAF	V600E	P110020	08/17/2011	Indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. 	MEL	Vemurafenib	BRAF	V600E	FFPE
cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc.)	Melanoma - Tissue	Cotellic (cobimetinib) NDA 206192 in combination with Zelboraf (vemurafenib) NDA 202429	NDA 206192  + NDA 202429	BRAF	V600E or V600K	P110020/S016	11/07/2016	Indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib by an FDA-approved test.	MEL	Vemurafenib + Cobimetinib	BRAF	V600E, V600K	FFPE
THXID BRAF Kit (bioMérieux Inc.)	Melanoma - Tissue	Mekinist (trametinib) NDA 204114	NDA 204114	BRAF	V600E or V600K	P120014	11/30/2017	Indicated, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test 	MEL	Trametinib	BRAF	V600E, V600K	FFPE
THXID BRAF Kit (bioMérieux Inc.)	Melanoma - Tissue	Tafinlar (dabrafenib) NDA 202806	NDA 202806	BRAF	V600E	P120014	05/29/2013	 Indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test	MEL	Dabrafenib	BRAF	V600E	FFPE